Primoris Wealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Primoris Wealth Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,987	Closed	-$237K	–	63
2022 Q2	$237K	Sell	1,987 -20	-1%	-$2.37K	0.34%	61
2022 Q1	$264K	Sell	2,007 -10,900	-84%	-$1.42M	0.25%	62
2021 Q4	$1.97M	Buy	+12,907	New	+$2M	1.59%	25

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Primoris Wealth Advisors's IBB Position: Q3 2022 in Review

Primoris Wealth Advisors sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 1,987 shares — an estimated $237K sold.

Primoris Wealth Advisors first reported a position in IBB in Q4 2021 and held it in 3 quarters. The position peaked at $1.97M in Q4 2021. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

Primoris Wealth Advisors reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
Primoris Wealth Advisors sold 1,987 iShares Biotechnology ETF shares in Q3 2022, an estimated $237K.
Primoris Wealth Advisors first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 3 quarters.
Primoris Wealth Advisors's iShares Biotechnology ETF position peaked at $1.97M in Q4 2021.
829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Primoris Wealth Advisors's 13F filing for Q3 2022, filed 20 Oct 2022.